The goal of the American Kidney Fund Clinical Scientist in Nephrology (CSN) fellowship program is to improve the quality of care provided to kidney patients and to promote clinical research in nephrology. The CSN program enhances the training of nephrologists who wish to pursue an academic career and whose primary professional commitment is to scholarship in the provision of patient care. Our CSN fellows conduct prevention and outcomes research while receiving advanced training in essential skills such as medical ethics, biostatistics and epidemiology.
The Clinical Scientist in Nephrology program was established in 1988, and since that time has trained some of nephrology's brightest scholars. Many former CSN fellows have gone on to distinguished careers in the field, conducting groundbreaking research that advances knowledge and treatment of kidney disease.
A Clinical Scientist in Nephrology fellowship may be granted yearly, with a maximum duration of two years for each fellowship. The maximum level of funding of $80,000 per year shall be used principally to support the candidate and his or her career development. This sum is expected to cover the individual fellow's salary (not to exceed $55,000) as well as training-related expenses.
The application for the 2019-2020 Clinical Scientist in Nephrology Program is now available. Completed applications must be received by November 30, 2018. Please direct all inquiries to Professional Education at firstname.lastname@example.org or 800.638.8299.
Meet the current CSN fellow
Katherine Wang, MD
Dr. Katherine Wang is currently a second-year nephrology fellow at Stanford University. She completed her undergraduate degree at the University of Rochester and her medical school and residency training in internal medicine at Albany Medical College.
As the 2018-2019 American Kidney Fund Clinical Scientist in Nephrology fellow, Dr. Wang’s research project is entitled SPRINTing to intensive blood pressure targets: when, for whom, and how?, will be an evaluation of the achievement of intensive blood pressure control in the Systolic Blood Pressure Intervention Trial (SPRINT).
“I am enthusiastic and earnest about this opportunity. I wholly believe in the American Kidney Fund’s commitment to fostering healthcare access, health literacy and prevention/progression of kidney disease,” said Dr. Wang.
Dr. Wang envisions an enriching career serving as an academic nephrologist. Her major interests are focused on improving hypertension outcomes, particularly in patients suffering with chronic kidney disease.